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Abstract
Background: Autosomal dominant hypercholesterolaemia (ADH) is 
a genetic disorder that is mainly resulted from defects in the low-
density lipoprotein receptor (LDLR) and apolipoprotein B-100 (APOB-
100) genes. Few studies of familial hypercholesterolaemia (FH) have 
been conducted in Malaysia, that makes the underlying main defect 
remains not well understood. 
Objectives: This study was aimed to describe the molecular aspects 
of FH among Malaysian subjects. 
Methods and Findings: We studied a group of 74 familial hyper-
cholesterolaemic patients and 77 healthy control subjects. The promo-
ter region and the 18 exons of the low-density lipoprotein receptor 
gene were screened by denaturing high-performance liquid chroma-
tography (DHPLC) to detect small deletions, insertions and nucleotide 
substitutions, while DNA sequencing was applied to look for gene 
variants in amplicons of exon 26 and 29 in the APOB-100 gene. A 
total of five gene sequence variants in the LDLR gene were reported 
in 54.1% of the studied patients. P.Arg471Arg variant has the highest 
frequency of 20.3% among the study subjects. One intronic mutation 
(c.313+1G>A) and one missense mutation (p.Arg 385Try) were found 
to be pathogenic, while the other three variants were reported to be 
non-pathogenic by the in silico analyses. Nine variants were reported 
in the APOB-100 gene among familial hypercholesterolaemic patients 
with a non-significant difference in their frequency from the control 
subjects. 
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Introduction
Familial hypercholesterolaemia (FH), (OMIM143890) 
is the first genetic disorder of lipid metabolism that 
is characterized both clinically and molecularly [1]. 
It is transmitted in an autosomal dominant manner 
[1]. Familial hypercholesterolaemia is characterized 
by elevated serum level of low density lipopro-
tein cholesterol (LDL-C) and total cholesterol (TC), 
tendon xanthomas (TX) and early atherosclerosis, 
leading to premature atherosclerotic coronary ar-
tery disease (CAD) [2, 3]. Heterozygous FH is the 
commonest monogenic disorder, that is affecting 
1 in 200–250, which is double as high as thought 
previously [4], with a penetrance rate of more than 
90 % [5]. The frequency can be higher in cer-
tain populations, such as the Afrikaners, French-
Canadians and Christian Lebanese [6] due to the 
founder effect [1]. Data from a large community 
study in Denmark suggested that the prevalence 
of FH may reach 1:137 [7]. Homozygous FH has a 
severe phenotype with an early symptoms during 
childhood [8].
Monogenic FH is mostly attributed to defects in 
low-density lipoprotein receptor (LDLR) gene. The 
LDLR gene was first discovered by Goldstein et al., 
it encodes for LDL receptor [9]. The LDLR gene com-
posed of 18 exons and is located at chromosome 
19 [10]. The LDLR gene defect was reported as the 
most common genetic cause of FH. Recently, the 
LOVD FH variant database describes 1741 mutations 
[11].
A similar phenotypic presentation to FH can be 
observed in patients with defective apolipoprotein B 
function (the main protein components of the LDL) 
[12]. Mutations in the apolipoprotein B-100 gene 
(APOB-100), can cause a clinical phenotype that is 
named as Familial Defective Apolipoprotein B-100 
(FDB). Mutations that can cause FDB are mostly re-
ported at the LDL binding domain of APOB-100 
gene, i.e at exons 26 and 29 of this gene [13].
Autosomal dominant hypercholesterolaemia 
(ADH) can also be a result of mutation in Propro-
tein Convertase Subtilisin/Kexin type 9 (PCSK9) gene 
that was identified on chromosome 1p32 [14]. 
Clinical management of FH should focus on its 
early diagnosis, coronary risk assessment, plus ma-
naging CAD risk factors as hypertension and glu-
cose intolerance, additionally reducing cholesterol 
level by the use of lipid lowering therapy in order 
to decrease atherosclerosis risk and subsequently 
prevents CAD [15]. It is often difficult to establish 
an accurate diagnosis for FH despite having various 
available international diagnostic criteria such as Si-
mon Broome’s Registry, Dutch Lipid Clinic Criteria 
and US MedPed [1]. Phenotypic criteria that requires 
details of the family history and detection of subtle 
physical signs such as arcus cornealis or xantomata 
that are frequently detected and are age depen-
dent, making them insensitive indicators for the cli-
nical detection of FH. 
It is believed that there are about 34 million FH 
cases globally [16]. In spite of the high prevalence of 
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Conclusions: Five LDLR gene sequence variants were reported. 
However, nine polymorphisms were stated in the APOB-100 gene. 
Those polymorphisms were not associated with FH phenotype among 
this cohort. These findings suggested that LDLR gene mutation is 
the major genetic cause for FH among Malaysians. The results offer 
information on the genetic spectrum of FH among Malaysian cohort 
which can serve as a platform for further genetic studies.
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FH and the considerable advantage of its early de-
tection and treatment, only around 1% of FH cases 
are diagnosed worldwide [16] with few exceptions 
where 71% in the Netherlands and 43% in Norway 
with FH were diagnosed [16]. 
Systematic genetic screening programs for muta-
tion detection in those who are clinically determined 
as FH have become less costly and can facilitate a 
better prognosis of the disease [17]. It was estimated 
that in the Asia-Pacific region alone, approximately 
3.6 million people are suffering from FH [18]. The 
International FH Foundation freshly announced gui-
delines for FH diagnosis [19], and in Asia, the Japa-
nese guidelines for FH have been recently published 
[20]. However, most of the genetic researches about 
FH were conducted in non-Asian populations with 
very few researches that were performed in South 
East Asia, specifically in Malaysia to determine the 
genetic mutations of FH [21-27]. 
Therefore, the current study was aimed to eluci-
date the molecular spectrum of FH among Malay-
sian subjects through the screening for mutations in 
the 18 exons and promoter region of LDLR gene, in 
addition to the exons 26 and 29 of APOB-100 gene.
Materials and Methods
Study population
Seventy four FH subjects from the Specialist Lipid 
and Coronary Risk Prevention Clinic of a teaching 
institution were recruited for this study. Familial hy-
percholesterolaemia was diagnosed based on the 
Simon Broome Familial Hypercholesterolaemia Re-
gister diagnostic criteria [28]. Patients with secon-
dary hyperlipidaemia such as those with diabetes 
mellitus, hypothyroidism and nephrotic syndrome, 
were excluded from the study [29]. 
Seventy seven normolipaemic controls were also 
taken on to detect any nucleotide substitutions 
that could be regarded as single nucleotide po-
lymorphism (SNP). The control subjects were ran-
domly chosen as healthy volunteers with TC level 
of < 6.5 mmol/L and/or LDL-C< 3.8 mmol/L with 
no previous history or family history of hyperlipi-
daemia or premature CAD, no history of secondary 
causes of hyperlipidaemia nor clinical signs of hy-
perlipidaemia. 
Demographic data, medical history, smoking ha-
bits, history of personal CAD and family history of 
premature CAD were documented. Physical exami-
nation for stigmata of hyperlipidaemia: presence of 
TX, xanthelasma, and arcus cornealis were recor-
ded. Blood pressure (BP) was measured with the 
subject in a seated position and after resting for 
5-10 minutes, BP was measured by an automated 
BP reader (cuff size 12 x 33cm, Colin press-mate, 
Japan). The systolic (SBP) and diastolic blood pres-
sures (DBP) were measured to the nearest 1 mmHg. 
Height and weight were measured to obtain BMI 
by using the formula: BMI=weight (kg)/height2 (m2). 
Presence of CAD was confirmed depending on the 
clinical history, previous medical records and exerci-
se tolerance test reports.
The study protocol was approved by the insti-
tutional research and ethics committees. Written 
informed consent was obtained prior to the com-
mencement of this study. 
Sample collection
Overnight fasting venous blood samples (4 ml) were 
collected from patients and controls into tubes con-
taining potassium ethylene diamine tetra acetic acid 
(EDTA). Genomic DNA was extracted by Maxwell® 
16 Blood DNA Purification kit on Maxwell® 16 Au-
tomated DNA Extraction System (Promega, USA). 
The samples were then stored at -20°C until further 
analysis. A further 6 ml of blood was collected into 
plain tubes and serum was separated within two 
hours of collection by centrifugation at 4,000 rpm 
for 7 minutes for biochemistry testing.
Routine biochemical analyses were performed for 
all subjects (both cases and controls) which consis-
ted of fasting serum lipid (FSL) that included TC, 
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triglyceride (TG), high density lipoprotein choleste-
rol (HDL-C) and LDL-C. Fasting plasma glucose, li-
ver function tests, renal profile and thyroid function 
test (composed of thyroid stimulating hormone, free 
thyroxine and tri-iodothyronine) were also measured 
to exclude secondary causes of hyperlipidaemia. TC, 
TG and HDL-C were performed on an automated 
analyser (Cobas Integra 400 plus, Roche Diagnos-
tics, Germany). LDL-C was derived using the Frie-
dewald calculation [30]. All these tests have been 
accredited by an international accredited body MS 
ISO 15189:2007 (SAMM no. 688).
Molecular analysis
Both patients and control subjects were screened 
for mutations in the LDLR and APOB-100 genes. All 
coding regions including intron-exon junctions of 
LDLR gene were screened based on the LDLR gene 
reference sequence that was obtained from the da-
tabase of the GenBank (accession no. NT_011295), 
the primers for LDLR gene were adapted from Bo-
dameret al., [31] (supplementary). 
For variants within the APOB-100 gene, the refe-
rence gene sequence was obtained from Genbank 
(accession no. NM_000384). Table 1 shows three 
sets of primers that were designed to amplify the 
previously reported variants associated with FDB in 
the APOB-100 gene as follows: one amplicon in 
exon 29 at nucleotides 12452-13113, that is related 
to codons 4151-4372; two amplicons in exon 26: 
one at nucleotides 10352-11632 that is related to 
codons 3451-3878, and the other at nucleotides 
7328-7818 that is related to codons 2443-2606.
PCR program for APOB-100 gene is illustrated in 
Table 1.
For the LDLR and APOB-100 genes, samples were 
analysed by PCR standardized using genomic DNA 
and primer pairs to amplify the target regions. One 
hundred nanograms of genomic DNA was mixed 
with 10X PCR buffer, 2 mM MgCl2, 200 µM deoxy-
nucleoside triphosphates, 2.5U of Taq polymerase 
and 0.2 µM of forward and reverse primers, res-
pectively. The amplification was performed in a final 
volume of 50 µl and carried out with the use of 
the Mastercycler Gradient (Eppendorf, Germany). 
Cycling conditions for the LDLR gene were 95 oC 
for 5 minutes, followed by 35 cycles at 95 oC for 
1 minute, 57 oC for 1 minute (except for exon 16, 
which was run at 65 oC),72 oC for 1 minute and 
final extension for 7 minutes at 72 oC.
The PCR reaction mixture was run in 2% aga-
rose gel electrophoresis with a 100-bp ladder for 
comparison.
DHPLC and direct sequencing
Using DHPLC, all patients and controls samples 
were investigated for point mutations, short de-
letions and duplications in the LDLR gene. Muta-
tion screening for LDLR gene was performed using 
partial denaturation mode of DHPLC on Wave Nu-
cleic Acid Fragment Analysis System (Transgenomic, 
USA). The melting temperature for each DNA frag-
ment was predicted using http://insertion.stanford.
edu./melt.html software. The PCR products were 
denatured at 95°C for 5 min and then cooled to 
65°C at a rate of 1°C/min. After slow re-annealing, 
Table 1. Primer sequences, PCR protocols and the expected amplicon size of APOB- 100 gene.
Exon
Primer 
name
Forward primer (5’ – 3’) PCR protocol
Product 
size (bps)
26
Primer A
F: GGAAACCAAGGCCACAGTTG 
R: GCGATACCTGCTTCGTTTGC
94oC, 3 min, 35 cycles (94oC, 60 s, 
59.8oC, 60 s, 72oC, 60 s), 72oC 10 min
311
Primer B
F: ACCGCTAAAGGAGCAGTTGA 
R:TCCTACCAATGCTGGTGGTGGTT
 94oC, 3 min, 35 cycles (94oC, 60 s, 
59.8oC, 60 s, 72oC, 60 s), 72oC 10 min
897
29
F:GAACTCTTAAGTTCCACATTGC 
R: CTGGGACACATAGTCTCTGC
94oC, 5 min, 35 cycles (94oC, 60 s, 
64oC, 30 s, 72oC, 30 s), 72oC 10 min
713
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it was essential to generate the heteroduplexes by 
mixing equal ammounts of subject samples and a 
wild type sample at the optimum temperature iden-
tified by mapping, the elution profile of the sample 
was compared to the elution profile of the control. 
Under partial denaturation temprature, the single 
peak pattern of the sample indicated the absence of 
mismatch i.e gene variant. In contrast, samples that 
showed different peak patterns from the controls 
were considered to be heteroduplex gene variants, 
and DNA sequencing of the purified PCR products 
of these samples was performed to confirm the re-
sults of DHPLC. For APOB-100 gene, PCR samples 
were preceded directly to sequencing to look for 
the variants that are located in LDL binding domain 
of the APOB-100 gene rather than screening the 
whole gene. PCR fragments were sequenced using 
the ABIPRISM Big Dye terminator cycle model ABI 
3730xl DNA Analyser (Applied Biosystem, USA) ac-
cording to the manufacturer’s recommendations.
In silico analyses of variant effects
Online computer programs were used to investigate 
the effects of the gene variants. All the variants 
were subjected to in silico analyses using Alamut 
Visual Version 2.7.1 that screens for splicing abnor-
malities as well as protein changes. Variants that 
were located within exons in which Alamut Visual 
could not predict any pathogenicity were subjec-
ted to analysis by Polymorphism Phenotyping (Poly 
Phen) software [32], which is an automatic tool for 
predicting the possible effect of an amino acid subs-
titution on the structure and function of a protein. 
Poly Phen software classifies amino acid substitu-
tions as benign, probably damaging, or possibly da-
maging. Nucleotide numbers were chosen using the 
LDLR gene sequence from http://www.ucl.ac.uk/fh 
database, with cDNA numbering that begins with 
A of ATG = 1. Mutations were named following 
the Human Genome Variation Society http://www.
hgvf.org. Mutation was defined as sequence chan-
ge which is clearly defined as FH causing, such as 
frameshift mutation also variants that are predicted 
to be pathogenic by in silico programs. 
Statistical analyses
The distribution of quantitative variables was tested 
for normality. An initial descriptive analysis was ca-
rried out using number of subjects and percentages 
for qualitative variables. Mean (SD) was used for 
quantitative variables. Student’s t-test was used to 
compare two groups. Categorical data and propor-
tions were analysed using Chi-square test. A p-value 
<0.05 was considered statistically significant. The 
statistical analysis was performed on the Statisti-
cal Package for Social Sciences (SPSS version 16.0) 
software.
Results
Study Subjects
A total of 74 FH patients (50 Malays and 24 Chinese) 
were collected.
 Sixty-one (82.4 %) patients were clinically diag-
nosed as definite FH and 13 (17.6 %) as possible FH 
according to the Simon Broome Criteria [28].
Their clinical characteristics are presented in Ta-
ble 2. Out of the 74 patients, 28 (37.8 %) were 
males while 46 (62.2 %) were females. Coronary 
artery disease was present in 27.4% of the pa-
tients. 
Table 2.  Background, clinical characteristics and lipid 
profiles of FH and control subjects.
Baseline 
Characteristics
FH group 
n=74
Control 
group n=77
P 
value
Age (years)*a 45.9 + 12 44.7 + 10.3 NS
Gender(%)b
Males 37.8 33.8
NS
Females 62.2 66.2
Current smoker (%)b 14.5 17.4 NS
Systolic BP (mmHg)*a 136.9 + 22.3 133.2 + 16.4 NS
Diastolic BP (mmHg)*a 77.8 ± 11.1 76.7 ± 10.8 NS
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Mutations Screening by DHPLC
LDLR gene variants were identified by analysing the 
promoter region and the exon-intron boundaries of 
the 18 exons of the LDLR gene using DHPLC, the 
heteroduplex peaks were further analysed by DNA 
sequencing to confirm the presence of the gene 
variants. 
Screening of all clinically diagnosed cases with 
FH revealed five LDLR gene variants among 40 out 
of the 74 clinically diagnosed FH patients (54.1%). 
None of the variants could be detected in the con-
trol group. The most frequent variant was the silent 
variant p.Asn591Asn that was reported among 19 
patients (25.6%). It resulted from the substitution 
of T>C at nucleotide 1773 in exon 12 (c.1773T>C). 
Patients who carried this variant had a high mean 
value for serum TC and a very high mean value for 
serum LDL-C according to the NCEP classification 
[29] (Table 3).
The second most common LDLR gene variant was 
c.1413G>A substitution in exon 10, resulting in the 
silent variant p.Arg450Arg, which was detected at 
a frequency of 20.3%.
Also the carries of this variant had a high mean 
value for serum TC and a very high mean value for 
serum LDL-C according to the NCEP classification 
[29] (Table 3).
One splice site mutation (c.313+1G>A) in intron 
3, was reported in a Chinese FH subject (1.3%). 
The patient had sever hypercholesterolaemia with 
serum TC and LDL-C values of 11.9 mmol/L and 9.8 
mmol/L, respectively (Table 3). 
In exon 5, p.Cys255Ser variant was reported 
among four FH patients from one family of Malay 
ethnicity (5.4%). They were found to carry this va-
riant of which one member was homozygous while 
the other three were heterozygous. The four FH 
patients presented with a mean of high TC and very 
high LDL-C values (9.9 ± 3.1 mmol/L) and (8.1 ± 3.1 
mmol/L), respectively [29], Table 3. The homozygous 
FH patient for this variant presented with prominent 
xanthelasma, corneal arcus and xanthomata with 
severely elevated TC, TG and LDL-C levels of 15.3 
mmol/L, 1.4 mmol/L and 13.5 mmol/L, respectively 
and HDL level of 1.2 mmol/L, whereas, the hete-
rozygotes FH patients presented with corneal arcus 
and xanthomata only. 
Another variant reported in this study was found 
in exon 9 which is p.Arg385Try. This variant was 
identified in a Chinese male. The identified patient 
Baseline 
Characteristics
FH group 
n=74
Control 
group n=77
P 
value
Hypertension (%)b 20.4  9.0 <0.05
Tendon Xanthomas(%) 85.1 -
Corneal Arcus (%) 95.9 -
Xanthelasma (%) 20 -
Glucose (mmol/L)*a 5.2 + 0.5 4.8 + 011 <0.01
BMI (kg/m2 )*a 24.3 ± 4.6 23.0 ± 4.6 NS
WHR*a 0.84 ± 0.07 0.81 ± 0.06 <0.05
Waist circumference 
(cm)*a
84.2 + 12.0 78.2 + 11.2 <0.001
Central Obesity (%)b 45.9 27.0 <0.005
CAD (%)b 27.4 0 <0.001
TC (mmol/L)*a 8.6 + 0.2 5.4 + 0.1 <0.001
TG (mmol/L)*a 2.0+ 0.2 1.3 + 0.6 <0.001
LDL-C (mmol.L)*a 6.4 + 0.2 3.4 + 0.1 <0.001
Death and Dyeing 70.05 70.05 81.25
HDL-C (mmol/L)*a 1.3 ± 0.4 1.4 ± 0.3 <0.001
*: Data expressed as mean ± SD, NS: not significant. BMI: Body 
mass index, BP: Blood pressure, CAD: coronary artery disease. a: 
independent T test was used, b: Chi square test was used.
Table 3.  Different mutation categories of LDLR gene 
and lipid profile parameters among FH pa-
tients (n=74).
Mutation categories in 
LDLR gene (%)A
Lipid profile parameters 
TC 
(mmol/l)
LDL-C 
(mmol/l)
HDL-C 
(mmol/l)
p.Asn591Asn (25.6%)B 8.1 ± 1.3 5.9 ± 1.2 1.3 ± 0.3
p. Arg450Arg (20.3%)B 8.0 ± 0.8 5.8 ± 0.9 1.3 ± 0.3
p.Cys255Ser (5.4%)B 9.9 ± 3.1 8.1 ± 3.1 1.4 ± 0.3
c.313+1G>A (1.3%) 11.9 9.8 1.2
p.Arg385Try (1.3%). 8.9 6.6 1.4
A: Percentage within the study group of 74 subjects. B: Groups are 
presented as mean (SD).
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with heterozygous p.Arg385Try mutation presen-
ted with high TC and very high LDL-C levels of 8.9 
mmol/L and 6.6 mmol/L, respectively [29] (Table 3).
In silico analyses
Alamut Visual software identified the two synon-
ymous variants, p.Asn591Asn and p.Arg471Arg as 
non-pathogenic because there were no evidence of 
splicing aberrations or changes in protein structure, 
although it may stall translation by requiring the 
use of low abundance tRNAs. The selected SNP ID 
was obtained from the NCBI database, (Table 4).The 
c.313+1G>A variant was classified as pathogenic 
splice site mutation as it can disrupt the normal 
splicing process, (Table 4).
For the missense mutation (p.Arg 385Try), it was 
classified as pathogenic by Alamut Visual software, 
while PolyPhen predicted it as probably damaging. 
The p.Cys255Ser variant was predicted to be Dele-
terious by SIFT and probably damaging by Polyphen 
software, (Table 4).
Based on the in silico analyses results, the two sy-
nonymous variants were reported as non pathoge-
nic, while the other three mutations were discovered 
to be pathogenic, these results bring together the 
mutation detection rate for this research of about 
8.1%(c.313+1G>A, p.Arg 385Try and p.Cys255 Ser 
with frequencies of 1.3%, 1.3% and 5.4%, respec-
tively).
APOB-100 Gene Sequencing Analysis
Concerning the APOB-100 gene, Nine variants were 
identified in the study subjects (Table 5). 
The frequency of the gene variants among FH 
patients and the control group was shown in Ta-
ble 5.
No significant difference could be reported for 
all the variants between FH and the control groups.
All the variants were exposed to in silico analy-
ses. p.Gly2540Val gene variant was reported to be 
Table 4.  LDLR gene variants detected among FH subjects 
Location Variant name* n(%) Reference In-silico analysis
Intron
3
c.313+1G>A 1(1.3%) LDLR_00442**
Pathogenic Disrupt normal splicing 
No SIFT or polyphen analysis
Exon 
5
c.763T>A; 
p.Cys255Ser
4(5.4%)
Azian et al., 
Alicezah et al., Alyaa et al.
SIFT: deleterious.
Polyphen: probably damaging
Exon 
9
c.1216C>T; 
p.Arg 385Try
1(1.3%) LDLR_00451**
Pathogenic SIFT: Deleterious
PolyPhen: probably damaging
Exon
10
c.1413 G > A; 
p.Arg471Arg
15(20.3%) Rs5930***
Synonymous Unlikely to cause
pathogenicity
Exon
12
c.1773T>C; 
p.Asn591Asn
19(25.6%)
LDLR_01195** 
Rs 688*** 
Synonymous Unlikely to cause pathogenicity
*: Naming of the variants was done according to Nomenclature of the Human Genome Variation Society (HGVS). **: www.ucl.ac.uk/ldlr/
LOVDv.1.1.0/. ***: Rs reference sequence from NCBI
Table 5.  APOB-100 gene defect in FH patients and 
control subject
APOB-100 
gene variant A
FH group 
çn=74
Control 
group n=77 p-value*
No % No %
Exon 26
p.Thr2515Thr 10 13.5 11 14.3 0.8
p.Gly2540Val 1 1.4 2 2.6 0.1
p.Ile2716Ile 2 2.7 1 1.3 0.1
p.Pro2739Leu 41 55.4 35 45.5 0.2
p.Thr3567Thr 0 0 1 1.3 0.3
Exon 26
p.Glu4181Lys 6 8.1 6 7.7 0.9
p.Arg4270Thr 3 4.1 5 6.5 0.5
p.Arg4297His 1 1.4 1 1.3 0.3
p.Ser4338Asn 35 47.3 36 46.7 0.9
A: Variant sequence name according to Nomenclature of the Human 
Genome Variation Society (HGVS). *: Chi- square test was used
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possibly damaging while p.Pro2739Leu was found 
to be probably damaging, the rest of the variants 
were established to be benign by Polyphen soft-
ware, Table 6.
Discussion 
At present, genetic diagnosis is the most precise 
method for diagnosing familial hypercholesteolemic 
patients. Although plentiful mutations were repor-
ted in the LDLR gene among FH patients, genetic 
data for the Malaysian population remain scarce 
[21-25]. The current study screened and investigated 
for both LDLR and APOB-100 genes variants from a 
cohort of clinically diagnosed definite and possible 
Malaysian FH patients.
The present study cohort of 74 patients with cli-
nical features of FH was relatively young (mean±SD 
age:45.9±12 years), and have a low prevalence of 
CVD (27.4%) compared to a previous study (32.6%) 
[33]. Together with an average LDL-C level of 6.4 
± 0.2 mmol/L which is also lower than the average 
LDL-C level for another FH population [33]. Such 
variation can be explained by the variation in the 
cardiovascular risk factors, the underlying causative 
mutation and the difference in the lifestyle among 
the respective population. 
The LDLR gene mutations were identified in 8.1% 
of clinically diagnosed FH patients. This result is 
lower than that reported among other Malaysian 
FH (42.2 %) [22] and among those who were collec-
ted by screening program for FH in the Netherlands 
(32.0%) [34], and Filipino FH (20%) patients [35]. 
This can be explained by the different inclusion cri-
teria that were used (Simon Broome). Additionally, 
because of the different screening methods which 
were used among the different studies. 
 Large rearrangements that may be present in the 
LDLR gene can increase the mutation detection rate 
if they were screened in this cohort. Furthermore, 
the presence of mutations or polymorphism in other 
candidate genes that are concerned to the LDL-C 
metabolisms, the co-existed environmental factors 
that may give to a similar phenotypic presentation 
as FH and finally the existence of LDLR gene muta-
tion in the introns of the gene, all these factors can 
increase the mutation detection rate in the study 
subjects. 
Five previously reported LDLR gene sequence va-
riations could be discovered in this research. Two 
pathogenic missense mutations and one intronic 
mutation (c.313+1G>A) could be reported.
The commonest variant that was reported in this 
study is p.Asn591Asn in exon 12, which was found 
in 25.6% of the patients. The frequent detection 
of a mutation may be the result of consanguinity, 
founder effect, frequent introduction of the mu-
tation into the cohort or can be due to recurrent 
mutational events, [36]. P.Asn591Asn variant was 
previously reported among the same ethnic group 
by Alyaa et al in a frequency of 4.3 % [22]. Also this 
synonymous variant was recently reported among 
possible FH cases of Azorean background in Por-
tugal [37] and among Russian FH population [38]. 
Table 6.  Gene variants in the APOB-100 gene among 
the study subjects.
Exon CodonA
Variant 
sequence 
nameB
Reference 
IDC
In silico 
analysisD
26
2515 p.Thr2515Thr Rs693 Benign
2540 p.Gly2540Val Rs571626569
Possibly 
damaging
2716 p.Ile2716Ile Rs 6413458 Benign
2739 p.Pro2739Leu Rs 676210
Probably 
damaging
3567 p.Thr3567Thr Rs12713558 Benign
29
4181 p.Glu4181Lys Rs10142031 Benign 
4270 p.Arg4270Thr Rs1801702 Benign 
4297 p.Arg4297His Rs375701380 Benign 
p.Ser4338Asn Rs1042034 Benign 
A: Numbering was done according to the accession no NP_000375.2 
from GenBank. B: Variant sequence name according to Nomenclature 
of the Human Genome Variation Society (HGVS). 
C: Reference ID from NCBI, D: In-silico analysis according to Polyphen
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The intronic mutation, c.313+1G>A has been pre-
viously described by Khoo and his colleagues of the 
same ethnic group [25]. This is the second report 
for this mutation among Malaysian cohort. This 
mutation, affecting the 5’ splice site domain(splice 
donor is deleted), was predicted to be a pathogenic 
by the in-silico analysis. According to Saphiro and 
Senapathy (1987) [39], it occurred within a conser-
ved 5’splice-donor site. Cameron et al reported that 
this mutation could result in skipping of exon 3 and 
inclusion of intron 3 [40].
In exon 5, p.Cys255Ser mutation has also been 
previously described in Malaysian FH population, 
[22, 27, 41]. It resulted in substitution of a Cystein 
by a Serine that may disrupt the ligand binding site 
of the LDLR gene so it may affect gene binding’s 
affinity to the LDL-C. 
While p.Arg 385Try mutation, at exon 9, was pre-
viously described among both Malaysian Azian et 
al [27] and Ashkenazi Jews populations [42]. It was 
reported as ‘probably damaging’ by in silico analysis.
p.Arg471Arg polymorphic variants was reported 
for the first time among Malaysian patients. How 
ever, it was previously reported among Russian FH 
population [43].
Both p.Asn591Asn in exon 12 and p.Arg471Arg 
in exon 10 variants are viewed as “silent,” and were 
found to be non-pathogenic by in sililco analysis. 
Which may indicate that they are not disrupting the 
normal splicing, codon usage, mRNA stability and 
folding, all these can adversely alter the normal pep-
tide synthesis [44].
Familial defective apoB is not able to be clinically 
distinguished from FH without genetic investigation. 
A variety of APOB-100 gene mutations have been 
identified in FDB patients [45, 46], while other FH 
research among Malaysian population were not 
able to detect mutations in the APOB-100 gene 
[24, 25, 41]. The present study was performed to 
screen for known and novel APOB-100 gene muta-
tions among subjects who are clinically diagnosed 
with FH. DNA sequencing was operated as a mu-
tation screening technique for the regions that are 
known to be crucial for the structural conformation 
of APOB-100 protein and its LDLR binding function 
[47, 48].
In the present study, nine variants were identified 
in the APOB-100 gene among the patients with no 
significant difference from the healthy controls, su-
ggesting that these are more likely polymorphisms 
rather than mutations, and all are previously repor-
ted in the NCBI database as polymorphisms. 
In the present study, p.Arg3500Glu mutation (the 
most common APOB-100 mutations) could not be 
identified, suggesting that this mutation is not a 
common variant in the Malaysian FDB cohort. This 
finding is similar to another FH study that was con-
ducted among Malaysians [46,41].
From this report, five polymorphisms (p.Thr2515Thr, 
p.Thr3567Thr, p.Arg4270Thr, p.Arg4297His and 
p.Ser4338Asn) were previously reported among 
Malaysians [46], while the rest, to the best of our 
knowledge, are reported for the first time among 
Malaysian FDB patients. 
p.Gly2540Val variant was predicted to be Possibly 
damaging while p.Pro2739Leu variant was predic-
ted to be Probably damaging by in silico analysis. 
However, family and in vitro studies are needed to 
confirm the pathogenesis of this variant.
In conclusion, among the 74 studied FH patients, 
we found five variants in the LDLR gene (one re-
ported for the first time among Malaysian FH) and 
nine polymorphisms in the APOB-100 gene (four 
reported for the first time among Malaysians) which 
indicate that LDLR gene variants appear to be a 
more leading cause to the FH phenotype rather 
than the APO B- 100 gene variants among Malay-
sian FH patients.
Future studies involving larger sample size of 
FH cases that can achieve a better representation 
of the general population plus genetic studies on 
other genes mutations that can be responsible for 
the ADH phenotype such as PCSK9 and LDLR-AP1 
(Low Density Lipoprotein Receptor Adaptor Protein 
InternatIonal archIves of MedIcIne 
sectIon: GenetIcs & GenoMIcs 
ISSN: 1755-7682
2016
Vol. 9 No. 182
doi: 10.3823/2053
This article is available at: www.intarchmed.com and www.medbrary.com 10
1), may further contribute to the development of 
the genetic information about FH among Malay-
sians.
We recommend the use of microarray analy-
sis that can be designed to detect the novel and 
the known variants in LDLR and APOB-100 genes 
among Malaysian FH subjects. A combination of 
such highly sensitive and specific technique to-
gether with the detection of large rearrangements 
by Multiplex Ligation dependent Probe Amplifica-
tion (MLPA) plus screening of other genes that may 
lead to FH phenotype will considerably increase the 
mutation detection rate among the study subjects. 
Additionally, those discovered mutations need for 
further confirmatory studies among families of in-
dex cases to highlight if they are associated with 
hypercholesterolaemia among the family members 
or no. In heterogeneous population such as in Ma-
laysia, the presence of mutations in other candidate 
genes such as PCSK9 may possibly cause hypercho-
lesterolaemia in the clinically-diagnosed FH patients. 
Mutations identification in these genes may contri-
bute to gain a better understanding of the diversity 
of disease-causing genes in FH. 
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